WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998051333) USE OF FACTOR XIII FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF REPERFUSION INJURY AND MUCOSAL DAMAGE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/051333    International Application No.:    PCT/US1998/009742
Publication Date: 19.11.1998 International Filing Date: 12.05.1998
Chapter 2 Demand Filed:    12.11.1998    
IPC:
A61K 38/45 (2006.01)
Applicants: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US)
Inventors: DEISHER, Theresa, A.; (US).
BISHOP, Paul, D.; (US).
GARCIA, Richard, M.; (US)
Agent: LUNN, Paul, G.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US)
Priority Data:
60/046,468 14.05.1997 US
Title (EN) USE OF FACTOR XIII FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF REPERFUSION INJURY AND MUCOSAL DAMAGE
(FR) UTILISATION DU FACTEUR XIII POUR LA FABRICATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES LESIONS DUES AUX PERFUSIONS REPETEES ET DES LESIONS DES MUQUEUSES
Abstract: front page image
(EN)Ischemic reperfusion injury, occurring spontaneously or resulting from ischemia induced to facilitate a surgical intervention, is reduced by administration of factor XIII in a biologically compatible vehicle. In addition, a factor XIII-containing pharmaceutical composition may be used to preserve the integrity of the mucosa or epithelium from damage caused by radiation or chemotherapeutic agents.
(FR)On réduit les lésions ischémiques dues aux perfusions répétées, qui se produisent de manière spontanée ou qui résultent d'une ischémie induite pour faciliter une intervention chirurgicale, en administrant le facteur XIII dans un excipient biologiquement compatible. En outre, on peut utiliser une composition pharmaceutique renfermant le facteur XIII pour préserver les muqueuses ou l'épithélium des lésions causées par les rayonnements ou les agents chimiothérapeutiques.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)